From the June 2017 issue of HealthCare Business News magazine


“If you can see it smaller and you see it earlier, you can better guide the patient to a more effective treatment strategy,” says Amy Burris, GE’s marketing leader for PET/CT. “It was also designed with the hope of pushing the boundaries of PET and conducting more compelling research within oncology, cardiology and neurology.”

The Discovery MI allows for the detection of smaller lesions, Burris says, and its high sensitivity allows enhanced utilization of limited-access tracers. It also has a 20-centimeter axial field of view option, which provides a more comfortable patient experience with short scan times with less dose, according to Burris.


For the Discovery NM/CT 670 CZT, which uses Cadmium Zinc Telluride (CZT)-based digital technology, the most significant feature is the ability to further optimize dose and acquisition time along with smaller lesion detectability, says Luke Chrusciel, GE’s marketing leader for SPECT/CT.

“The reduction in time means the patients can have more comfortable exams, and therefore, exams are less likely to be compromised due to potential patient movement associated with prolonged imaging times,” Chrusciel says.


The company’s Discovery TM 670 DR can be upgraded at a customer site to the CZT technology, which Chrusciel calls the “future of nuclear medicine,” in two days.

“This is the beginning of a new era in nuclear medicine, going from analog to digital in general purpose imaging,” Chrusciel says. “We are proud again to lead the industry in this space like we have done so previously by being the first to market with a hybrid SPECT/CT system.”

In the PET/MR space, GE earlier this year received FDA clearance for the follow-up to its SIGNA PET/MR system, called SIGNA PET/MR with QuantWorks. The technology includes Q.Clear reconstruction that improves image quality and quantification of tracer uptake with personalized attenuation correction in the head.

Mediso
Mediso’s newest release is the AnyScan TRIO SPECT/CT, a system that blends preclinical and clinical technology with a three-headed scanner, which scans the patient faster and provides better angular positioning, says Gabor Nemeth, director of preclinical imaging for Mediso.

This is an upgrade from the original AnyScan, which has a dual-headed scanner.

June 2017 Magazine

Read more stories from the June 2017 issue

More Magazine Features

Molecular Imaging Homepage